ROIV
ROIV
$35.90
per share, on-chain
What ROIV does
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- Industry
- Healthcare
- CEO
- Matthew Gline
- Website
- roivant.com
Ways to own ROIV
There's one version of this stock on Firstshare.
OndoROIVonOur pick
Wider choice. Usually $20 minimum, and it can cost more when New York is closed.
Daily backing report (29 Oct) ↗Monthly backing report (Sep 2026) ↗
$35.90
Closed until New York opens
Price check
What a slice looks like
$10.00 buys you 0.28 of one ROIV share.
That's 27.9% of one share. Small, but it's yours, and it moves with the real price. One share costs $35.90.